StockNews.AI
ADIL
StockNews.AI
34 days

Adial Pharmaceuticals Regains Compliance with Nasdaq Stockholders' Equity Listing Requirement

1. Adial regained compliance with Nasdaq listing rule on July 14, 2025. 2. CEO highlights this as a step towards reinforcing investor confidence. 3. Adial focuses on therapies for addiction, including AUD and other disorders. 4. ONWARD trial for AD04 showed promising results in heavy drinking patients. 5. No overt safety concerns were reported during the ONWARD trial.

7m saved
Insight
Article

FAQ

Why Bullish?

Regaining compliance with Nasdaq enhances credibility and investor confidence, which may positively affect stock price. Previous instances of compliance regained led to increased investor interest and stock recovery.

How important is it?

Compliance reaffirms financial health and potential for future collaborations, crucial for investor relations. Gains in stock equity and increased investor confidence can significantly impact stock performance.

Why Short Term?

The immediate market sentiment can be positively influenced by compliance news. However, long-term effects will depend on trial successes and product development progress.

Related Companies

AD04
July 16, 2025 08:30 ET  | Source: Adial Pharmaceuticals, Inc GLEN ALLEN, Va., July 16, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it received notice from Nasdaq on July 14, 2025 that the Company has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain stockholders' equity of at least $2,500,000. Cary Claiborne, President and Chief Executive Officer of Adial, commented, “We’re pleased to have regained compliance with Nasdaq, a key step in reinforcing investor confidence and supporting our long-term growth strategy. This reflects our commitment to disciplined financial management as we continue advancing our pipeline and creating value for shareholders.” About Adial Pharmaceuticals, Inc. Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company’s ONWARD™ pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the Company’s companion diagnostic genetic test. ONWARD showed promising results in reducing drinking in heavy drinking patients, and no overt safety or tolerability concerns. AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Additional information is available at www.adial.com. Forward-Looking Statements This communication contains certain “forward-looking statements” within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. The forward-looking statements include statements regarding reinforcing investor confidence and supporting our long-term growth strategy, the commitment to disciplined financial management, continuing to advance the Company’s pipeline and creating value for shareholders and the potential of AD04 to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Any forward-looking statements included herein reflect our current views, and they involve certain risks and uncertainties, including, among others, our ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, our ability to develop strategic partnership opportunities and maintain collaborations, our ability to obtain or maintain the capital or grants necessary to fund our research and development activities, our ability to complete clinical trials on time and achieve desired results and benefits as expected, regulatory limitations relating to our ability to promote or commercialize our product candidates for specific indications, acceptance of our product candidates in the marketplace and the successful development, marketing or sale of our products, our ability to maintain our license agreements, the continued maintenance and growth of our patent estate and our ability to retain our key employees or maintain our Nasdaq listing. These risks should not be construed as exhaustive and should be read together with the other cautionary statement included in our Annual Report on Form 10-K for the year ended December 31, 2024, subsequent Quarterly Reports on Form 10-Q and current reports on Form 8-K filed with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law. Contact: Crescendo Communications, LLC David Waldman / Alexandra Schilt Tel: 212-671-1020 Email: adil@crescendo-ir.com

Related News